Andrographis paniculata has robust clinical evidence for reducing URTI symptoms, with multiple RCTs and a systematic review/meta-analysis showing significant superiority over placebo. The Kan Jang product (Andrographis + Eleutherococcus senticosus) is the most-studied formulation, with Swedish and Armenian trials demonstrating reduced symptom duration and severity. However, the EMA/HMPC declined to establish a monograph because the requirements for either "well-established use" or "traditional use" within the EU framework were not met. This is primarily because Andrographis is not part of European traditional medicine (originating from Ayurvedic and Traditional Chinese Medicine). It is registered as an approved herbal medicine in several Scandinavian countries under national procedures. Safety is generally excellent, but rare anaphylactic reactions have been reported.

Astragalus membranaceus is one of the most important herbs in Traditional Chinese Medicine (TCM) for immune support ("tonifying Qi"), with thousands of years of documented use and extensive Chinese-language clinical research. However, it occupies a precarious position in Western evidence-based phytotherapy: it has no Commission E monograph, no ESCOP monograph, no EMA/HMPC monograph, and very limited high-quality Western clinical trial data. The active compounds (astragaloside IV, astragalus polysaccharides, formononetin) have well-characterized immunomodulatory mechanisms in preclinical studies. The herb is very safe even at high doses but lacks the European regulatory infrastructure that characterizes the other herbs in this module. It represents the widest gap between traditional reputation and Western evidence in this collection.

Baikal skullcap (Scutellaria baicalensis) is one of the 50 fundamental herbs in Traditional Chinese Medicine, where the dried root is known as Huang Qin and has been used for over 2,000 years to "clear heat and drain dampness." The root contains the flavones baicalin, baicalein, and wogonin, which are among the most extensively studied plant-derived anti-inflammatory compounds, demonstrating potent inhibition of NF-kB, COX-2, and 12/15-lipoxygenase pathways as well as broad antiviral activity against influenza, RSV, and SARS-CoV-2. Huang Qin is a key component of the classical formula Xiao Chai Hu Tang (Sho-saiko-to in Japanese Kampo), which has the most substantial clinical trial evidence of any formula containing this herb, particularly for chronic hepatitis. Despite extensive preclinical and pharmacological research, standalone clinical RCT data for Scutellaria baicalensis remains limited; there are no European monographs (Commission E, ESCOP, or EMA/HMPC), though growing Western interest in baicalein as a drug candidate continues to expand the evidence base.

Cat's Claw (Uncaria tomentosa) is a woody vine from the Amazon rainforest with a long history of use in South American indigenous medicine for inflammatory and immune-related conditions. The inner bark contains two chemotypes of oxindole alkaloids -- pentacyclic (POA, considered therapeutic: isopteropodine, mitraphylline) and tetracyclic (TOA, considered antagonistic) -- along with quinovic acid glycosides, procyanidins, and sterols. Limited clinical evidence suggests anti-inflammatory activity in osteoarthritis (one RCT showing benefit for knee OA) and immune-stimulating properties (increased white blood cell count). A Cochrane-style systematic review found insufficient evidence for most claimed indications. Commission E has not issued a monograph, nor has ESCOP, though EMA has not assessed it either. The WHO has published a monograph. Cat's Claw exemplifies a traditional Amazonian remedy with pharmacological plausibility but insufficient clinical trial evidence to support strong therapeutic claims.

Chaga (Inonotus obliquus) is a parasitic fungus growing on birch trees in northern latitudes, used in Russian, Scandinavian, and Baltic folk medicine for centuries as a general health tonic, typically prepared as a decoction or tea. The sclerotium contains beta-glucans, betulin and betulinic acid (derived from birch bark), melanin complexes, triterpenoids (inotodiol, lanosterol), and polyphenols with exceptional in vitro antioxidant activity. Preclinical research shows anti-inflammatory, immunomodulatory, and cytotoxic effects, but no human clinical trials have been published for any indication. Despite enormous consumer popularity and marketing claims, chaga has the weakest evidence base of the major medicinal mushrooms. No regulatory body (Commission E, ESCOP, EMA) has assessed it. Evidence rating E reflects traditional use only with no clinical substantiation.

Cordyceps is a prized tonic fungus from traditional Chinese and Tibetan medicine, historically one of the most expensive medicinal substances in the world due to wild-harvested Ophiocordyceps sinensis scarcity; today it is primarily available as cultivated Cordyceps militaris, which shares a similar active compound profile. The key bioactives -- cordycepin (3'-deoxyadenosine, an adenosine analog) and immunomodulatory beta-glucan polysaccharides -- underpin clinical evidence for improved exercise performance and VO2 max, fatigue reduction, and immune modulation. While small randomized trials support these applications, large-scale confirmatory studies are still needed. Cordyceps falls outside the European phytotherapy regulatory framework.

Echinacea is the most extensively studied herbal immunomodulator, with 20+ RCTs and a Cochrane review. However, the clinical evidence remains frustratingly heterogeneous because different species, plant parts, and preparation types have been tested. European regulators have addressed this by issuing separate monographs for each species/part combination. E. purpurea aerial parts (fresh pressed juice) have the strongest European endorsement and most clinical data. The Cochrane review concludes that some Echinacea products may reduce cold incidence and duration, but the evidence is not definitive. Commission E approved E. purpurea herb, E. purpurea root, and E. pallida root for different indications.

Elderberry (Sambucus nigra fruit) has some of the most compelling clinical trial data of any herbal immunomodulator for acute respiratory viral infections, with a meta-analysis showing a large effect size (d=1.717) for reducing duration of upper respiratory symptoms. The key Zakay-Rones 2004 trial showed influenza recovery in 3-4 days vs. 7-8 days for placebo. Despite this, the EMA/HMPC declined to issue a monograph for elderberry fruit (while accepting elderflower) because documentation of 30-year traditional medicinal use at a specified dosage was deemed insufficient. This regulatory gap highlights the sometimes arbitrary nature of the EU traditional use framework. Elderberry is generally very safe with a favorable risk-benefit profile.

Eleuthero (Eleutherococcus senticosus) occupies a historically important but evidentially awkward position in phytotherapy. It was the subject of extensive Soviet-era research by Brekhman and colleagues who coined the modern concept of "adaptogens," and it received a positive Commission E monograph in Germany -- one of only a handful of herbs formally recognized as adaptogens by any Western regulatory body. The EMA/HMPC also adopted a monograph (2008) for "symptoms of asthenia such as fatigue and weakness." However, modern systematic reviews consistently find that the clinical evidence is heterogeneous, of low quality, and insufficient to make strong efficacy claims by current standards. The herb is very safe, with no significant toxicity even at high doses, and has a well-characterized phytochemical profile (eleutherosides). It is a component of the Kan Jang product (with Andrographis) for URTI treatment. The EU-US divergence is notable: regulatory recognition in Europe but minimal cl

Goji berry (Lycium barbarum) is one of the most important tonic herbs in Traditional Chinese Medicine (Gou Qi Zi), used for over 2,000 years to nourish Liver and Kidney yin, replenish Jing (essence), and brighten the eyes. Lycium barbarum polysaccharides (LBP), comprising 5-8% of the dried fruit, are the primary bioactive fraction with well-characterized immunomodulatory, antioxidant, and neuroprotective effects through activation of macrophages, dendritic cells, NK cells, and T lymphocytes via TLR2/TLR4-NF-kB signaling. The fruit is also among the richest dietary sources of zeaxanthin (as zeaxanthin dipalmitate, 0.5-1.2 mg/g dry weight), and two randomized trials have demonstrated increased macular pigment optical density with daily goji berry intake. Limited but growing clinical evidence supports benefits for immune enhancement, general wellbeing, and in vivo antioxidant status, though most trials are small and short-term. A clinically important warfarin interaction has been documented in multiple case reports, mediated by CYP2C9 inhibition, causing markedly elevated INR and bleeding. Goji berry has no European regulatory monographs (Commission E, ESCOP, or EMA/HMPC).

Moringa (Moringa oleifera) is a fast-growing tropical tree called the "Miracle Tree" due to its exceptional nutritional density -- the leaves contain all essential amino acids, significant vitamins (A, C, E, B-complex), minerals (calcium, iron, potassium), and bioactive compounds including isothiocyanates (moringin), flavonoids (quercetin, kaempferol), and phenolic acids (chlorogenic acid). Clinical trials, mostly small, show promising effects on blood glucose regulation, lipid profiles, and inflammatory markers. The isothiocyanate moringin activates Nrf2 antioxidant pathways and shows immunomodulatory activity. No European regulatory monographs exist, though moringa is extensively documented in Ayurveda and is recognized as a significant medicinal plant by the WHO for nutritional applications in developing countries. Evidence is moderate -- nutritional benefits are well-established, but clinical evidence for specific therapeutic claims remains limited by small sample sizes.

Oregano oil is a popular supplement marketed primarily for immune support and antimicrobial activity. The essential oil is rich in the phenolic monoterpenes carvacrol (typically 60-80%) and thymol (typically 1-5%), which demonstrate potent broad-spectrum antimicrobial activity in vitro against bacteria, fungi, and some parasites. However, the clinical trial evidence for oregano oil in humans is extremely limited and does not match its commercial popularity. One small open-label study (Chedid et al. 2014) included oregano as part of a multi-herb protocol for SIBO that showed equivalence to rifaximin, but oregano oil was not isolated as a single intervention. A Phase I trial of carvacrol confirmed safety in healthy subjects. No Commission E, ESCOP, or EMA monograph exists for oregano oil specifically. The herb is generally safe at recommended supplement doses, but essential oil ingestion carries inherent risks and should be distinguished from culinary use of dried oregano herb.

Pelargonium sidoides root extract EPs 7630 (Umckaloabo) is one of the best-evidenced herbal medicines in European phytotherapy, with 10+ RCTs involving over 2,000 patients demonstrating efficacy for acute bronchitis. It received full marketing authorization in Germany in 2005 -- not merely traditional use registration -- and has an EMA/HMPC monograph. The extract works through a unique triple mechanism: immunomodulation (cytokine and NK cell activation), antibacterial activity (anti-adhesion, not bactericidal), and cytoprotective/antiviral effects. It is one of the top-selling OTC medicines in German pharmacies. The evidence base is substantially stronger than for most herbal medicines, with robust meta-analyses showing reduced sick days and faster recovery from acute bronchitis.

Reishi (Ganoderma lucidum) is the "Mushroom of Immortality" in traditional Chinese medicine, with over 2,000 years of documented use for promoting longevity and vitality. Its primary bioactive constituents -- beta-glucan polysaccharides and ganoderic acid triterpenoids -- have demonstrated immune-modulating effects through activation of innate immune cells including macrophages, NK cells, and dendritic cells. Clinical studies, including a Cochrane review of five RCTs, support adjunctive use in cancer patients for immune function and quality of life improvements, though direct antitumor effects have not been demonstrated. Traditional indications for sleep, anxiety, and cardiovascular support are backed by preliminary mechanistic data but lack robust clinical trials. Reishi falls outside the European phytotherapy regulatory framework.

Rhodiola rosea is the most formally recognized adaptogen in European phytotherapy, being the only herb with an EMA/HMPC monograph specifically for stress-related symptoms. The 2012 HMPC monograph approved it as a traditional herbal medicinal product for temporary relief of stress symptoms such as fatigue, exhaustion, and sensation of weakness. The SHR-5 standardized extract (3% rosavins, 1% salidroside) is the most clinically studied preparation, with RCTs demonstrating significant anti-fatigue effects, improved mental performance under stress, and potential antidepressant activity. The herb acts primarily through HPA axis modulation, monoamine neurotransmitter effects, and neuroprotective mechanisms. Safety is excellent with a very large therapeutic margin, but clinically relevant CYP3A4 and CYP2C9 inhibition warrants attention for drug interactions.

Turkey Tail (Trametes versicolor) is one of the most extensively researched medicinal mushrooms, valued primarily for its immune-modulating polysaccharide complexes PSK (polysaccharide-K, marketed as Krestin) and PSP (polysaccharopeptide). PSK has been approved as an adjuvant cancer therapy in Japan since 1977 and has been studied in over 20 randomized controlled trials involving thousands of patients with colorectal, gastric, and lung cancers, with meta-analyses demonstrating statistically significant improvements in 5-year overall survival rates when combined with standard chemotherapy. PSP is approved as a Category II drug in China for similar indications. The primary mechanism involves beta-glucan-mediated stimulation of innate and adaptive immunity through TLR2 and Dectin-1 receptor activation, enhancing NK cell cytotoxicity, CD8+ T cell proliferation, and dendritic cell maturation. While the Japanese and Chinese clinical data are substantial, Western clinical research remains in early phases, and product standardization outside pharmaceutical-grade PSK/PSP remains a significant challenge.